Facet’s Dana Blue Returns to AMWA Regulatory Writing Subcommittee for 2026
Shaping The Future of Regulatory Writing Education Facet Life Sciences [...]
Why Separating Regulatory and Commercial Strategy Can Kill an Otherwise Promising Biotech
For many small biotech teams, regulatory and commercial strategies are [...]
Behind the Scenes of a Productive Nonclinical Type C Meeting Strategy
How a novel pediatric gene therapy developer leveraged regulatory gap [...]
Leveraging Breakthrough Therapy Designation (BTD) for Gene Therapy Development
What every developer should know to maximize BTD value by [...]
Leveraging Development Opportunities in Radiopharmaceuticals
By Randy Goodman, PhDIn the evolving landscape of innovative therapeutics, [...]
Facet Life Sciences and XCancer Announce Strategic Partnership to Advance Theranostic Clinical Trials
Facet Life Sciences, a leader in regulatory strategy and drug development services, today announced a strategic partnership with XCancer®, a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology.
gET sOCIAL